ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock par value $0.012 per share
Symbol
ORMP on Nasdaq
Shares outstanding
41,009,592
Price per share
$2.96
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
9,209,933
Total reported value
$24,309,179
% of total 13F portfolios
0%
Share change
-14,346
Value change
+$25,894
Number of holders
47
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
KIDRON NADAV 7.6% $6,638,633 3,116,729 Nadav Kidron 11 Feb 2025
BML Investment Partners, L.P. 6.6% $5,816,595 2,643,907 BML Investment Partners, L.P. 31 Dec 2024

As of 30 Sep 2025, 47 institutional investors reported holding 9,209,933 shares of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP). This represents 22% of the company’s total 41,009,592 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) together control 22% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BML Capital Management, LLC 7.7% 3,167,231 +2.7% 7.7% $8,361,490
Aquamarine Financial (Cayman) Ltd 4.8% 1,973,057 0% 0.53% $5,208,870
Murchinson Ltd. 4.3% 1,751,559 0% 0.89% $4,624,116
BOOTHBAY FUND MANAGEMENT, LLC 2.1% 845,391 0% 0.06% $2,231,832
Rathbones Group PLC 0.57% 233,018 0% 0% $615,167
BANK OF AMERICA CORP /DE/ 0.36% 149,667 +4.4% 0% $395,121
RENAISSANCE TECHNOLOGIES LLC 0.36% 148,900 +3.3% 0% $393,096
DIMENSIONAL FUND ADVISORS LP 0.36% 147,487 -12% 0% $389,365
WELLS FARGO & COMPANY/MN 0.32% 130,086 +520% 0% $343,426
CITADEL ADVISORS LLC 0.27% 111,707 +28% 0% $294,906
BlackRock, Inc. 0.27% 109,733 +28% 0% $289,696
JANE STREET GROUP, LLC 0.15% 59,659 +41% 0% $157,500
RBF Capital, LLC 0.1% 42,947 0% 0.01% $113,380
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.09% 36,825 -24% 0% $97,218
Squarepoint Ops LLC 0.07% 29,866 -35% 0% $78,846
Connor, Clark & Lunn Investment Management Ltd. 0.07% 28,243 -53% 0% $74,562
GEODE CAPITAL MANAGEMENT, LLC 0.06% 24,282 0% 0% $64,104
XTX Topco Ltd 0.06% 23,885 0% $63,056
PNC Financial Services Group, Inc. 0.06% 23,200 0% 0% $61,248
AMERICAN CENTURY COMPANIES INC 0.05% 19,591 0% 0% $51,720
WEALTH ENHANCEMENT ADVISORY SERVICES, LLC 0.05% 18,799 0% 0% $46,622
MORGAN STANLEY 0.04% 16,924 -47% 0% $44,680
Sage Capital Management, LLC 0.04% 16,750 0% 0.02% $44,220
LPL Financial LLC 0.03% 13,585 -7.5% 0% $35,864
BARCLAYS PLC 0.03% 13,198 0% 0% $34,843

Institutional Holders of ORAMED PHARMACEUTICALS INC. - Common Stock par value $0.012 per share (ORMP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 35,049 $103,916 -$2,063 $2.96 2
2025 Q3 9,209,933 $24,309,179 +$25,894 $2.64 47
2025 Q2 7,251,222 $16,313,647 -$1,132,788 $2.25 47
2025 Q1 7,771,787 $16,633,500 +$194,000 $2.14 52
2024 Q4 7,666,141 $18,551,607 +$1,150,587 $2.42 56
2024 Q3 6,959,875 $16,982,253 +$2,490,137 $2.44 55
2024 Q2 5,933,749 $15,249,519 +$1,726,907 $2.57 58
2024 Q1 5,261,652 $15,365,000 +$367,171 $2.92 51
2023 Q4 5,157,802 $11,912,739 +$6,481,828 $2.31 56
2023 Q3 2,294,903 $5,988,449 -$130,636 $2.61 55
2023 Q2 2,276,672 $8,150,136 -$6,048,074 $3.58 50
2023 Q1 4,261,808 $9,288,923 -$8,600,260 $2.18 58
2022 Q4 3,602,106 $43,330,122 +$3,052,928 $12.03 75
2022 Q3 3,938,125 $25,517,588 -$15,544,475 $6.48 66
2022 Q2 6,646,450 $30,636,409 -$17,757,938 $4.58 81
2022 Q1 9,033,365 $78,273,671 -$349,248 $8.65 99
2021 Q4 8,576,111 $122,411,193 +$40,878,901 $14.28 114
2021 Q3 5,412,384 $118,854,258 +$35,544,918 $21.98 91
2021 Q2 3,842,761 $51,413,524 +$35,140,443 $13.38 73
2021 Q1 1,235,726 $64,175,840 +$52,410,474 $10.16 43
2020 Q4 1,455,367 $6,169,000 -$1,608,413 $4.24 36
2020 Q3 2,003,232 $5,190,000 +$1,670,327 $2.61 34
2020 Q2 1,349,404 $4,725,000 +$2,515,869 $3.53 31
2020 Q1 624,185 $1,899,000 -$91,414 $3.04 29
2019 Q4 624,437 $3,215,000 -$401,395 $5.14 30
2019 Q3 759,036 $2,420,000 -$260,031 $3.19 28
2019 Q2 839,001 $3,010,000 -$842,076 $3.59 26
2019 Q1 1,073,145 $3,905,000 -$2,620,760 $3.64 25
2018 Q4 1,898,942 $5,699,000 +$412,711 $3.00 24
2018 Q3 1,741,007 $8,449,000 +$7,167,466 $4.85 28
2018 Q2 263,431 $1,958,000 +$6,399 $7.43 21
2018 Q1 256,435 $1,666,000 -$820,544 $6.51 20
2017 Q4 377,714 $3,402,549 +$790,106 $9.00 27
2017 Q3 274,779 $2,725,000 +$1,262,094 $9.92 22
2017 Q2 148,752 $1,157,000 +$276,760 $7.78 21
2017 Q1 148,282 $909,000 +$37,679 $6.10 20
2016 Q4 139,267 $850,000 -$374,754 $6.05 23
2016 Q3 181,737 $1,320,000 -$246,428 $7.26 21
2016 Q2 220,940 $1,841,000 +$300,003 $8.34 23
2016 Q1 201,186 $1,318,000 -$124,121 $6.65 24
2015 Q4 210,282 $1,781,840 +$388,209 $8.55 23
2015 Q3 156,424 $854,000 -$1,037,671 $5.47 18
2015 Q2 334,950 $1,904,000 -$1,476,942 $5.68 13
2015 Q1 543,520 $3,371,822 -$1,225,552 $6.37 14
2014 Q4 824,403 $3,758,000 -$864,806 $4.56 19
2014 Q3 1,375,959 $11,127,000 -$423,614 $8.07 18
2014 Q2 1,426,930 $13,726,430 +$928,265 $9.62 22
2014 Q1 1,311,737 $15,304,000 +$5,082,819 $11.78 21